AIM ImmunoTech Inc. AIM
AIM ImmunoTech Inc. (NYSE: AIM) is an oncology drug developer. Its lead program, Ampligen (rintatolimod) + durvalumab (DURIPANC), is in Phase 2 for late-stage pancreatic cancer. Its next catalyst on record is Ampligen + cisplatin + pembrolizumab (ovarian, NCT03734692): Completion of secondary endpoint data collection (January 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Ampligen + cisplatin + pembrolizumab (ovarian, NCT03734692) — Completion of secondary endpoint data collection (January 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Alferon N Injection (interferon alfa-n3) | refractory/recurring external genital warts | protein/peptide | Approved |
| Ampligen + Imfinzi (DURIPANC, Phase 1b/2) | metastatic pancreatic cancer | oligonucleotide-other | Phase 2 |
| Ampligen AMP-270 (randomized Phase 2) | locally advanced pancreatic adenocarcinoma | oligonucleotide-other | Phase 2 |
| Ampligen + cisplatin + pembrolizumab (NCT03734692) | advanced recurrent ovarian cancer | oligonucleotide-other | Phase 2 |
| Ampligen + aspirin +/- IFN (NCT03899987) | early-stage prostate cancer | oligonucleotide-other | Phase 2 |
Recent results and decisions
- Feb 5, 2026positive Year-end interim update from ongoing Phase 2 DURIPANC (18 enrolled) reports continued promising PFS and OS, no significant toxicity and high quality of life; no numeric efficacy values given.
According to Erasmus MC, there has also been no significant toxicity – an encouraging safety profile for a post-chemo setting – and Ampligen subjects are consistently reporting “high quality of life” during treatment.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.